Deconvoluting the 'omics' for organ transplantation.
OBJECTIVE
The desire for biomarkers for diagnosis and prognosis of diseases has never been greater. With the availability of genome data and an increased availability of proteome data, the discovery of biomarkers has become increasingly feasible. This article reviews some recent applications of the many evolving 'omic technologies to organ transplantation.


RESULTS
With the advancement of many high-throughput 'omic techniques such as genomics, metabolomics, antibiomics, peptidomics, and proteomics, efforts have been made to understand potential mechanisms of specific graft injuries and develop novel biomarkers for acute rejection, chronic rejection, and operational tolerance.


CONCLUSIONS
The translation of potential biomarkers from the laboratory bench to the clinical bedside is not an easy task and will require the concerted effort of the immunologists, molecular biologists, transplantation specialists, geneticists, and experts in bioinformatics. Rigorous prospective validation studies will be needed using large sets of independent patient samples. The appropriate and timely exploitation of evolving 'omic technologies will lay the cornerstone for a new age of translational research for organ transplant monitoring.
Sarwal
Minnie M
MM
Department of Pediatrics, Stanford University, Stanford, California, USA. msarwal@stanford.edu
D015415:Biomarkers / Q000378:metabolism*; D019295:Computational Biology / Q000379:methods; D023281:Genomics / Q000379:methods*; D006084:Graft Rejection / Q000378:metabolism*; D006801:Humans; D016377:Organ Transplantation / Q000379:methods*; D010455:Peptides / Q000737:chemistry; D040901:Proteomics / Q000379:methods*
D015415:Biomarkers; D010455:Peptides